India’s Weight-Loss Drug Revolution

We’re in the last month of 2024, and a lot of things have defined this year: elections, wars, artificial intelligence. One phenomenon that’s been making waves is weight-loss drugs, especially ones like Ozempic. The world got a peek at them in 2022, they triggered a storm in 2023, and this year they’ve become the new normal. Well, not in India just yet, but that could change very soon. Reports suggest that Novo Nordisk, the Danish drug maker behind Ozempic and Wegovy, is pushing for an early launch in India. 

Some context: Novo Nordisk has been at the forefront of this global weight-loss drug revolution. These drugs are so popular that the company struggled to keep up with demand. Right now, Novo Nordisk is Europe’s most valuable company. However, neither Ozempic nor Wegovy is available in India yet. Initially, the plan was to launch these drugs in 2026. But now, Novo Nordisk wants to fast-track things and bring them here as early as next year. Why the rush? They’re worried about losing India as a market, thanks to competition from Eli Lilly, an American pharmaceutical giant. Eli Lilly, with its own weight-loss drugs — Mounjaro and Zepbound — has already received India’s drug regulator’s approval for use in Type 2 diabetes. Weight-loss approval is still under review, but it’s expected as early as 2025. Novo Nordisk doesn’t want to fall behind, especially when the stakes in India are so high. 

Let’s zoom out for a moment: Why are these companies battling it out over India? The numbers tell the story. India has 80 million obese individuals and another 225 million who are overweight. On the global obesity rankings, India comes in third, right after the US and China. By 2034, 11% of the Indian population is projected to be obese, making it a goldmine for weight-loss drugs. The demand is already there. In 2022, India’s weight management market was valued at $180 million. By 2028, it’s projected to hit $336 million. And while weight-loss drugs aren’t legally available here yet, thousands of people are already finding ways to get their hands on them — whether by smuggling, importing from Europe, or even buying counterfeit versions online. The catch? These drugs are outrageously expensive. Ozempic costs around $1,000 per month (that’s over ₹80,000), while Wegovy is even steeper at $1,300 per month (more than ₹1 lakh). At these price points, they’re unaffordable for most Indians. 

So, what’s the solution? There are two potential ways to make these drugs accessible: 

1. **Indian Pharma Giants Join the Game** Companies like Sun Pharma and Cipla are already developing alternatives. Early tests are promising, and these drugs could hit the market soon. 
2.  **Patent Expiry** Novo Nordisk’s drugs rely on an active ingredient called semaglutide, which they currently hold a patent for. Once the patent expires in India in 2026, Indian pharma companies will be able to produce generic versions, potentially slashing prices. By 2026, we’re likely to see a mix of foreign players, local brands, and generic versions flooding the market. 

But let’s not lose sight of a bigger issue here. India’s health landscape is unique and deeply paradoxical. While 80 million people struggle with obesity, millions more face malnutrition. Over 800 million Indians rely on food subsidies, and an even larger number lack sufficient nutrition. This stark contrast — one part of the population struggling with excess while another battles with access — is a glaring reminder of the inequalities that persist. It’s a call to bridge these gaps and create a future where health isn’t a privilege but a universal right.